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SYNE2Regulation of nuclear protein import is central to many cellular processes such as development, with a key
mechanism being factors that retain cargoes in the cytoplasm that normally localize in the nucleus. The breast
cancer antigen BRCA1-binding protein BRAP2 has been reported as a novel negative regulator of nuclear im-
port of various nuclear localization signal (NLS)-containing viral and cellular proteins, but although implicated
in differentiation pathways and highly expressed in tissues including testis, the gamut of targets for BRAP2
action in a developmental context is unknown. As a ﬁrst step towards deﬁning the BRAP2 interactome, we
performed a yeast-2-hybrid screen to identify binding partners of BRAP2 in human testis. Here we report char-
acterization for the ﬁrst time of three of these: the high mobility group (HMG)-box-domain-containing chro-
matin component HMG20A, nuclear mitotic apparatus protein NuMA1 and synaptic nuclear envelope protein
SYNE2. Co-immunoprecipitation experiments indicate association of BRAP2 with HMG20A, NuMA1, and
SYNE2 in testis, underlining the physiological relevance of the interactions, with immunohistochemistry
showing that where BRAP2 is co-expressed with HMG20A and NuMA1, both are present in the cytoplasm,
in contrast to their nuclear localization in other testicular cell types. Importantly, quantitative confocal micro-
scopic analysis of cultured cells indicates that ectopic expression of BRAP2 inhibits nuclear localization of
HMG20A and NuMA1, and prevents nuclear envelope accumulation of SYNE2, the ﬁrst report of BRAP2 alter-
ing localization of a non-nuclear protein. These results imply for the ﬁrst time that BRAP2may have an impor-
tant role in modulating subcellular localization during testicular development.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Protein transport into and out of the nucleus through the nuclear
pore complexes embedded in the nuclear envelope [1–5] is a highly
regulated process that is central to many cellular processes, including
development. Proteins greater than 40–60 kDa in size require a nu-
clear localization signal (NLS) in the cargo protein that is recognized
by members of the importin superfamily of protein transporters
[2,4], generally either the importin α/β heterodimer [2,5], or one of
the many importin β homologues independent of importinα. Nuclear
import can be tightly regulated through a number of mechanisms,
including cytoplasmic retention, whereby cargo proteins are boundmp, BRCA1Associated Protein 2/
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l rights reserved.by cytoplasmic factors and as a result, are retained within the cyto-
plasm [4].
A cytoplasmic retention factor of interest in this context is the
BRCA1-associated binding protein 2 (BRAP2; also known as Impedes
Mitogenic Signal Propagation or Imp), ﬁrst identiﬁed as a cytoplasmic
protein recognizing the NLS of the breast cancer antigen BRCA1 [3].
Consistent with a role in cellular differentiation, BRAP2 appears to inter-
actwith the cyclin-dependent-kinase-inhibitor p21 duringmonocyte dif-
ferentiation. Both nuclear and cytoplasmic forms of p21 appear to carry
out distinct functions; nuclear p21 acts as a cell cycle brake, whereas
cytoplasmic p21 has various roles, including protection against apoptosis,
promotionof neurite growth indevelopingneurons, and facilitation of as-
sembly and nuclear translocation of cyclin D/Cdk4 complexes [6]. BRAP2
has also been shown to act as a cytoplasmic retention factor for speciﬁc
viral proteins such as the SV40-Large Tumor-Antigen (T-ag) and human
cytomegalovirus processivity factor ppUL44 [1,7] in a phosphorylation-
dependent fashion, aswell as inhibitingnuclear transport of other cellular
proteins such as p53 [1].
BRAP2 has more recently been implicated in a diverse range of
signaling pathways, in part involving ubiquitinylation/neddylation.
Through the E3 ubiquitin ligase activity of its RING domain, for example,
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the Cell division cycle gene 14 (HsCdc14A) [8]; BRAP2 has also been
shown to co-localizewithHsCdc14A onmitotic spindle poles, suggesting
a potential role for it in cell cycle regulation [8]. Alterations in BRAP2
have been observed in conditions such as myocardial infarction [9] and
carotid atherosclerosis, where a buildup of lipid components within the
arterial walls leads to nuclear factor-κB (NF-κB)-dependent recruitment
of inﬂammatory cytokines. This appears to relate in part to BRAP2's abil-
ity to interact with both IκB (Inhibitor of κB) β and IκB Kinase (IKK) β,
both of which are components of the IKK-signalosome, which is respon-
sible for phosphorylation/degradation of IκB [10], the canonical cytoplas-
mic retention factor for NF-κB [11]. IκBβ sequesters NF-κB in the
cytoplasm, while IKKβ stimulates Iκβ degradation in response to the
secretion of inﬂammatory cytokines, to allow NF-κB to translocate to
the nucleus; upregulation of BRAP2, dependent on interaction with
IKK, can enhance NF-κB nuclear translocation [10]. BRAP2 has also
been shown to interact with Cul1, a cullin family protein that undergoes
the ubiquitin-like modiﬁcation neddylation, and makes up part of the
Skp, Cullin, F-box containing multi-protein E3 ubiquitin ligase SCF com-
plex, responsible for mediating degradation of Iκβ [11]. Interestingly,
BRAP2 possesses a consensus neddylation sequence similar to those
possessed by cullin family proteins, and is able to bind Cul1 itself, in re-
sponse to Tumor necrosis factor-α stimulation, to help suppress NF-κB
nuclear translocation in response to cytokine stimulation [11]. This effect
of BRAP2 on the NF-κB pathway is antagonistic to that which occurs as
a result of its interaction with IKK (above), presumably a result of the
complex interaction between BRAP2 and Cul1 [11]. Finally, BRAP2 is
known to inhibit the ERK signal transduction pathway following lytic
cycle activation post Epstein–Barr virus infection, by interacting with
KSRI (kinase suppressor of Ras 1) [12], a scaffold protein responsible for
mediating complexation between Raf, MEK (mitogen activated protein
kinase) and ERK (extracellular signal-regulated kinase) [13]. BRAP2/Imp
can also suppress interferon-γ secretion in response to T-cell receptor
activation [14].
Interestingly, BRAP2 is expressed in the testis to a much higher
extent than in other tissues [15], implying a potentially critical role
in testicular germ cell development. Essentially nothing, however, is
known of BRAP2's binding partners, or its functional role in the testis.
Here we address this question for the ﬁrst time, performing a yeast
2-hybrid screen using a human testis cDNA library to begin to deﬁne
the BRAP2 interactome. Of a number of interacting partners identiﬁed,
three are characterized in detail; the high mobility group (HMG)-
box-domain-containing chromatin component HMG20A, the nuclear
mitotic apparatus protein NuMA1 and synaptic nuclear envelope pro-
tein SYNE2. The results not only validate interaction with BRAP2 in tes-
tis, but implicate particular testicular germ cells, such as the pachytene
spermatocytes, as a key site of BRAP2 action for the ﬁrst time. Most
importantly, BRAP2 is shown for the ﬁrst time to be functional as a
cytoplasmic retention factor for HMG20A, NuMA1 and SYNE2, and
hence likely to play a critical developmental role in the testis.
2. Materials and methods
2.1. Yeast two-hybrid screen
Yeast 2-hybrid screening was performed by Hybrigenics Inc.
(Paris, France). Brieﬂy, amino acids 343–592 of human BRAP2 were
cloned into vector pB27 (derived from pBTM116) to encode the
C-terminal LexA fusion protein, N-LexA-BRAP-C, which was used as a
bait to screen a cDNA library from human testes, constructed in plasmid
p6 (derived from plasmid pGADGH) [16]. A mating strategy [17] was
used to screen 146 million clones, using yeast strains Y187 (matα)
and L40ΔGal4 (mata) and 179 HIS positive colonies were selected
from amedium lacking tryptophan, leucine and histidine, but substitut-
ed with 5 mM 3-aminotriazole to prevent bait autoactivation. Prey
fragments of the positive clones were ampliﬁed at their 3′ and 5′ endsand the sequences produced from PCRwere used to identify interacting
proteins from the GenBank™ database (NCBI). A conﬁdence score (PBS,
Predicted Biological Score) was allocated to each interaction, to enable
interacting clones to be prioritized.
2.2. Expression plasmid construction
GFP-fused BRAP2 (encoding amino acids 2–592 and 343–592) and
coilin (amino acids encoding 2–112) expression vectors were con-
structed using the Gateway system (Invitrogen, Carlsbad, CA, USA)
[1], in the plasmid pDONR207 or pDONR222 expression vectors re-
spectively. LR recombination reactions were subsequently performed
using the Gateway-compatible destination vector pEPI-RfC [18] to
generateGFP-fusion protein-encoding constructs formammalian cell ex-
pression, as previously described [19]. An additional construct was gen-
erated by PCR ampliﬁcation of the region encoding BRAP2(343–592)
and cloned into the expression vector pHM830 [20] between the AﬂII
and AgeI restriction endonuclease sites to encode the fusion protein
GFP-BRAP2(343–592)-β-galactosidase. The integrity of all constructs
was veriﬁed by DNA sequencing.
2.3. Cell culture
Cells of the COS-7 African green monkey kidney or HeLa human
cervical cancer lines were maintained in DMEM containing 10% fetal
calf serum in a 5% CO2 humidiﬁed incubator at 37 °C [1].
2.4. Transfection/immunoﬂuorescence
Cells seeded onto glass coverslips were transfected using
Lipofectamine® 2000 (Invitrogen) according to the manufacturer's
speciﬁcations. 16 or 40 h post transfection, cells were ﬁxed [1] and
incubated in anti-SV40 T-ag (Santa Cruz, 1:750) or anti-SYNE2
(Sapphire Bioscience, 1:100) monoclonal antibodies, or anti-HMG20A
(ProteinTech Group, 1:100) or anti-NuMA1 (Abcam, 1:100) polyclonal
antibodies, followed by incubation with Alexa 568-labeled goat anti-
rabbit secondary antibody or Alexa 568-labeled rabbit anti-mouse sec-
ondary antibody (Invitrogen, 1:1000). Coverslips were mounted onto
slides using ProLong® Gold Anti-Fade Reagent (Invitrogen), containing
the DNA-speciﬁc dye 4,6-diamidino-2-phenylindole (DAPI) or 4%
propyl gallate, as appropriate.
2.5. CLSM and image analysis
Cells immunostained for endogenously expressed proteins or
transfected to express GFP-fusion proteins were imaged on a Nikon
C1 inverted microscope as previously described [1] using a Nikon
100× oil immersion lens. The nuclear to cytoplasmic ﬂuorescence
ratio (Fn/c) was determined as previously described [1] from digi-
tized images using the ImageJ 1.43r public domain software (NIH),
statistical analysis performed using a 2-tailed unpaired t-test and
the GraphPad Prism 5.0c software.
2.6. Co-immunoprecipitation/Western analysis
All studies that were carried out complied with the NHMRC Code
of Practice for the Care and Use of Animals for Experimental Purposes,
and were conﬁrmed by the Monash University Standing Committee
on Ethics in Animal Experimentation. Wild type adult mouse testes
from inbred mice (C57/BL6-Jx129SV) were obtained from Monash
University Central Animal Services. The animals were killed by cervi-
cal dislocation prior to dissection and decapsulation of the testes.
Following PBS washes, testes were homogenized using RIPA buffer
(150 mM sodium chloride, 1% NP40, 0.5% sodium deoxycholate,
0.1% SDS, 50 mM Tris, pH 8) containing a protease inhibitor cocktail
(Roche). Cellular debris was removed by centrifugation at 20,000 ×g
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determined by Bradford assay (Biorad). Co-immunoprecipitation was
performed using the Catch and Release® v2.0 Reversible Immunopre-
cipitation System (Upstate Cell Signalling Solutions) according to the
manufacturer's instructions, using 4 μg of anti-HMG20A, anti-NuMA1,
anti-SYNE2, anti-BRAP2 (Sigma), anti-(HIS)6 (BD Pharmingen) or
anti-GFP (Roche) antibodies. Following overnight incubation, proteins
were eluted from the beads with 70 μl or 50 μl, as appropriate, 1×, 2×
and 4× non-denaturing buffer and 1× denaturing buffer, respectively,
and subjected to SDS-polyacrylamide gel electrophoresis (12% gel,
with 8% for NuMA1).
GFP-fusion proteins were immunoprecipitated from HEK293T cell
lysates using the Protein A/G PLUS-Agarose immunoprecipitation re-
agent (Santa Cruz Biotechnology) as previously described [1]; 30 μl of
the eluate was subjected to SDS-polyacrylamide gel electrophoresis
(12% gel).
After electrophoresis, proteins were transferred to Polyvinylidene
Fluoride (PVDF) membranes (PALL Corporation) preactivated in
isopropanol (Merck) and Western blotting carried out as previously
described [1]. Brieﬂy, the membrane was blocked in 5% skim milk
powder in PBS/0.05% Tween 20 (Amresco) and incubated for 1 or
2 h with rabbit primary anti-BRAP2 (1:1000), anti-NuMA1 (1:1000
or 1:100, as appropriate), anti-HMG20A (1:1000 or 1:200, as appro-
priate) or anti-SYNE2 (Sigma, 1:300) antibodies. Subsequently, blots
were incubated in HRP-coupled goat anti-rabbit secondary antibody
(Millipore, 1:10,000), for 1 h and detected using enhanced chemilu-
minescence (ECL) (Perkin Elmer) according to the manufacturer's
instructions.
2.7. Lysate preparation/Western analysis
Adult rat testis lysateswere prepared from60 to 90 day-old Sprague
Dawley outbred rats, while adult mouse testis lysatewas prepared from
C57 black mice, as per Section 2.6. Isolated rodent spermatogonia,
round spermatids, and pachytene spermatocytes were extracted and
isolated as previously described [21].
Lysates (30 μg) were subjected to SDS-polyacrylamide gel elec-
trophoresis (8% gel) and Western transfer, blocking, incubation
with antibodies and ECL detection performed essentially as above
(Section 2.6).
2.8. Immunohistochemistry
Immunohistochemistry on Bouins-ﬁxed parafﬁn-embedded day
15 and 30 and adult mouse testes from Asmu:Swiss mice was per-
formed as previously described [22]. The tissues were incubated with
anti-BRAP2 (1:500), anti-HMG20A (1:100) or anti-NuMA1 (1:100)
antibodies made up in TB, overnight in a humid chamber at 4 °C, and
subsequently incubated with a biotin-conjugated sheep anti-rabbit
antibody (Millipore, 1:500) at room temperature. Following incubation
with Vectastain® (Vector Laboratories), washing, treatment with 3,3′-
diaminobenzidine/activation with H2O2, and counterstaining with
Harris' Hematoxylin (BioRad), slides were mounted onto coverslips
using DPX (di-n-butyl-phthalate in xylene) mounting solution (Sigma).
Samples were imaged using a bright ﬁeld microscope (Provis) with
either a 40 or 100× oil immersion lens.
3. Results
3.1. Identiﬁcation of testicular binding partners of BRAP2
Although BRAP2 is highly expressed in testis, there is no information
as to its binding partners in the testis/potential targets for regulation of
nuclear localization. To address this, a human testis cDNA library was
screened using humanBRAP2 in the yeast 2-hybrid system.Of a number
of high conﬁdence potential binding partners with 7–30 individualclones identiﬁed for each, three were selected for further investigation:
theHMG-box-domain-containing chromatin componentHMG20A [23],
NuMA1, a structural nuclear protein expressed during interphase that is
thought to function in linking microtubules to the spindle poles during
mitosis, and the nuclear envelope protein SYNE2, which is believed to
play a role in linking the nucleus and cytoskeleton [24].
3.2. BRAP2 interacts with HMG20A, NuMA1 and SYNE2 in mouse testis
To conﬁrm interaction, co-immunoprecipitationwas performed from
lysates from adult mouse testis using speciﬁc antibodies to HMG20A,
NuMA1, SYNE2 or BRAP2, with anti-(HIS)6 or anti-GFP antibodies as
controls. Western analysis was used to detect co-immunoprecipitated
protein and its binding partners (Fig. 1). Endogenous BRAP2 co-
immunoprecipitated with the anti-HMG20A, -NuMA1 and -SYNE2 anti-
bodies, but failed to be pulled down using the anti-(HIS)6 antibody
(Fig. 1A), indicating that BRAP2 is indeed found in complexes with
these proteins in adult mouse testis. The co-immunoprecipitations
were performed using anti-BRAP2 antibodies, endogenous SYNE2 and
NuMA1 being able to be co-immunoprecipitated with the anti-BRAP2
antibody but not control antibodies (anti-(HIS)6 or anti-GFP antibodies)
respectively (Fig. 1B). Detection of HMG20A in anti-BRAP2 immunopre-
cipitates did not prove possible for technical reasons, but immunoprecip-
itation using anti-GFP antibody after ectopic expression of the fusion
protein GFP-BRAP2(343–592) in HEK293T cells enabled detection of en-
dogenous HMG20A, in contrast to cells expressing GFP alone as a control
(Fig. 1C), thus conﬁrming the interaction. Clearly, BRAP2 is able to inter-
act with HMG20A, NuMA1 and SYNE2.
3.3. HMG20A and NuMA1 are cytoplasmic in mouse testicular cell types
expressing BRAP2
mRNA expression data from a mouse testis age series for BRAP2
and its three binding partners indicate dynamic changes in expres-
sion levels (Fig. 2A); BRAP2 increases in expression from c. day 14/
16, whereas HMG20A, NuMA1 and SYNE2 all show decreasing ex-
pression post day 14/16. Western analysis for BRAP2 protein levels
conﬁrmed this, with higher expression evident in adult (mouse and
rat) testis lysates and isolated pachytene spermatocytes and round
spermatids, compared to spermatogonia (see Fig. 2B). Immunohisto-
chemistry to assess protein localization in situ was compared in testis
sections from day 15 and day 30 as well as adult mice [15], revealing
BRAP2 to be present in the cytoplasm of the pachytene spermatocytes
in all samples, but largely absent from the earlier cell types (Fig. 2C).
HMG20A was present in the nuclei of some of the early spermatogo-
nia in 15-day- and 30-day-old mouse testes, but was predominantly in
the cytoplasm of the pachytene spermatocytes from both day 15 and
day 30 mice (Fig. 2D). Similarly, NuMA1 was present in the cytoplasm
of the pachytene spermatocytes in 15-day-old mouse testis and in the
nuclei of some of the early spermatogonia and the nuclei and cytoplasm
of the round spermatids in day 30 mouse testis (Fig. 2D).
The results indicate that in the germ cell typeswhere BRAP2 appears
to be expressed to reasonable levels, its interactors HMG20A and
NuMA1 are cytoplasmic, in contrast to their predominantly nuclear
localization in the earlier germ cell types where BRAP2 expression is
low. The clear implication is that interaction of BRAP2 with HMG20A
and NuMA1 in the testis (see Fig. 1) has functional consequences,
resulting in cytoplasmic retention of HMG20A and NuMA1 to prevent
their nuclear action in the later stages of spermatogenesis.
3.4. Ectopically expressed BRAP2 can act as a cytoplasmic retention
factor for HMG20A and NuMA1
To conﬁrm the ability of BRAP2 to have an effect of cytoplasmic
retention on HMG20A and NuMA1 implied by the results above, the
effect of BRAP2 on subcellular localization of endogenous HMG20A
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Fig. 1. BRAP2 interacts with HMG20A, NuMA1 and SYNE2 in adult mouse testis lysate. A. Co-immunoprecipitation (IP) was performed using lysates from wild type C57 black adult
mouse testes using the Catch and Release® v2.0 Reversible Immunoprecipitation System. Endogenous BRAP2 was co-immunoprecipitated using anti-HMG20A, anti-NuMA1 and
anti-SYNE2 antibodies, but failed to co-immunoprecipitate using an anti-(HIS)6 control antibody (top left). B. Endogenous SYNE2was co-immunoprecipitated using an anti-BRAP2 antibody,
but failed to co-immunoprecipitate using an anti-(HIS)6 antibody, while NuMA1 was co-immunoprecipitated using an anti-BRAP2 antibody, but failed to co-immunoprecipitate using an
anti-GFP control antibody (right). C. HMG20A was co-immunoprecipitated from HEK293T cell lysates transfected to express GFP-BRAP2(343–592), but failed to co-immunoprecipitate
with HEK293T cell lysates transfected with GFP alone (bottom left).
3439R.G. Davies et al. / Biochimica et Biophysica Acta 1833 (2013) 3436–3444and NuMA1, with T-ag as a positive control, was assessed. GFP fused
to BRAP2 residues 343–592, previously shown to be the key func-
tional domain for BRAP2 cytoplasmic retention activity [1], was ec-
topically expressed in COS-7 or HeLa cells, and its effects compared
to those of GFP alone. Brieﬂy, cells were immunostained 16 h post-
transfection using speciﬁc antibodies to the respective proteins and
Alexa 568-coupled secondary antibodies, were imaged using CLSM
(Fig. 3B/D, respectively). HMG20A resembled T-ag in showing strong
nuclear staining in the absence of BRAP2 in COS-7 cells, with increased
cytoplasmic staining evident in the presence of GFP-BRAP2(343–592),
but not GFP alone. Quantitative analysis conﬁrmed these results,where-
by determination of the nuclear to cytoplasmic ﬂuorescence ratio (Fn/c)
revealed that nuclear accumulation of the control T-ag wassigniﬁcantly (p b 0.0001; Fig. 3B/C) c. 25–30% reduced in the pres-
ence of GFP-BRAP2(343–592), consistent with previous results [1];
GFP alone had no signiﬁcant effect, conﬁrming the speciﬁcity of the
effects with respect to BRAP2. That this was a speciﬁc effect was in-
dicated by the fact that GFP fused to the coiled-coil domain (residues
2–112) of the Cajal body component coilin [25] did not inhibit T-ag
nuclear localization (Supp. Fig. 1) in contrast to GFP fused to
BRAP2; the clear implication is that the BRAP2 coiled-coil domain
confers speciﬁc binding/function in modulating nuclear transport,
in contrast to the coiled-coil domain of coilin that presumably has
more of a structural role.
Importantly, HMG20A showed results similar to those for T-ag, with
signiﬁcantly (p b 0.0001) almost 50% reduced nuclear accumulation/
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3441R.G. Davies et al. / Biochimica et Biophysica Acta 1833 (2013) 3436–3444increased cytoplasmic staining in the presence of GFP-BRAP2(343–592)
but not in the presence of GFP alone (Fig. 3D/E), strongly implying that
BRAP2 can act as a cytoplasmic retention factor for HMG20A in intact
cells to inhibit its nuclear import. Comparable experiments for
NuMA1 (Fig. 3F), revealed reduced nuclear accumulation/increased
cytoplasmic localization of endogenous NuMA1 in the presence of
GFP-BRAP2(343–592), with quantitative analysis (Fig. 3G) con-
ﬁrming signiﬁcant (p b 0.0001) almost 50% reduced nuclear accu-
mulation. These results clearly support the idea that like HMG20A,
NuMA1 is a target of the cytoplasmic retention activity of BRAP2.
3.5. BRAP2 is a cytoplasmic retention factor for SYNE2 in COS-7 cells
Subcellular localization of SYNE2 was similarly assessed, in HeLa
(data not shown) and COS-7 cells transfected to express the indicated
GFP-BRAP2 fusion proteins or GFP alone at 16 (Fig. 4) or 40 h (not
shown) post-transfection. In the absence of overexpressed BRAP2/in
the presence of overexpressed GFP alone, SYNE2 showed distinctive
nuclear rim staining (indicated by the white arrows) together with
diffuse cytoplasmic staining and cytoplasmic aggregates. In the pres-
ence of GFP-BRAP2(2–592) and GFP-BRAP2(343–592), in contrast,
localization of SYNE2 at the nuclear envelope was largely absent
(indicated by white arrow heads), with a corresponding increase in
diffuse cytoplasmic staining. These results suggest that, as for HMG20A
and NuMA1, SYNE2 subcellular localization can be modulated by
BRAP2's cytoplasmic retention activity.
4. Discussion
This is the ﬁrst study to indicate a role for the cytoplasmic reten-
tion factor BRAP2 in the mammalian testis, importantly documenting
its ability to alter subcellular localization of the nuclear proteins
HMG20A and NuMA1. We also show for the ﬁrst time that BRAP2
can modulate localization of the nuclear envelope protein SYNE2, im-
plying that BRAP2 has a role in modulating subcellular localization
that is not restricted to nuclear transport.
4.1. BRAP2 binds HMG20A, NuMA1 and SYNE2 in adult mouse testis
HMG20A, NuMA1 and SYNE2 are identiﬁed and validated here for
the ﬁrst time as binding partners of BRAP2 in the mammalian testis.
HMG20A belongs to the HMG box class of proteins, which encode
a DNA-binding domain that is involved in the regulation of transcrip-
tion and translation and plays a role in maintaining chromatin con-
formation [26]. HMG20A is ubiquitously expressed in many tissues
and may act as a non-histone component of chromatin or interact
with tissue-speciﬁc transcription factors [23]. By inhibiting nuclear
accumulation of HMG20A, BRAP2 may therefore be acting as an addi-
tional layer of transcriptional control. NuMA1 is a nuclear protein
expressed during interphase, but is also abundant at the spindle
poles of cells undergoing mitosis [27], where it forms complexes
with dynein and dynactin [28] to help link microtubules to the spin-
dle poles [29]; whether BRAP2 action plays a direct role in modulat-
ing spindle pole stability is unclear, but an intriguing idea in this
context is that modulation of NuMA1 nuclear localization in inter-
phase may contribute to the binding of NuMA1 to microtubules inFig. 2. Expression of BRAP2 in the same testicular germ cell types as HMG20A and NuMA1
relative levels of BRAP2, HMG20A, NuMA1 and SYNE2 mRNA expression throughout sper
BRAP2 of adult mouse/rat testis lysates, and isolated mouse testis cell types; from left to righ
ps, rat pachytene spermatocytes; rs, mouse round spermatids. C. Immunostaining for BRAP2 i
using 40× and 100× objectives indicates BRAP2 expression in the cytoplasm of the pachyte
between 40× and 100× sections immunostained for BRAP2, represent negative controls of
on 100× objective images is equivalent to 50 μm. D. Immunostaining for HMG20A and Nu
and the cytoplasm of the pachytene spermatocytes, in both 15-day-old and 30-day-old mous
matocytes in 15-day-old mouse testis sections and the nuclei of the early spermatogonia a
Panels to the left of sections immunostained for HMG20A, represent negative controls of ththe cytoplasm, which may subsequently be critical at the onset of
mitosis. SYNE2 belongs to the nesprin family of proteins, which are
characterized by the presence of multiple spectrin repeats, a bipar-
tite NLS motif and a conserved transmembrane domain [30], which
is important for nuclear envelope localization. SYNE2 also associates
with F-actin through actin-binding sites [31], thereby acting tomaintain
the structural integrity of the nucleus [24]. By regulating the nuclear/
nuclear envelope localization of SYNE2, BRAP2 may modulate nuclear
integrity, whichmay be important during the complex rearrangements
in chromatin and nuclear structure that occur in the later stages of
spermatogenesis.4.2. BRAP2 co-expression with HMG20A and NuMA1 in mouse testis
results in cytoplasmic localization
The immunohistochemical data here clearly indicates that BRAP2
protein is present within the cytoplasm of the pachytene spermato-
cytes in adult mouse testis, consistent with public domain affymetrix
data shown in Fig. 2A. Both HMG20A and NuMA1, normally nuclear
proteins, were found to be present within the cytoplasm of the pachy-
tene spermatocytes, suggesting an effect of BRAP2 expression on the
localization of both proteins in this cell type, consistent with BRAP2
acting as a cytoplasmic retention protein in the testis. Consistent with
this idea, HMG20A and NuMA1 are localized within the nucleus in cell
types such as the early spermatogonia, where BRAP2 is expressed at
low levels.4.3. BRAP2 can act as a cytoplasmic retention protein for HMG20A,
NuMA1 and SYNE2
In the case of HMG20A and NuMA1, BRAP2 interaction inhibits
nuclear accumulation, as has been observed for viral proteins such
as T-ag [1,2], but BRAP2 inhibition of nuclear envelope localization
of SYNE2, represents the ﬁrst time BRAP2 cytoplasmic retention activity
has been shown to affect subcellular trafﬁcking other than that of nucle-
ar import. That the results are physiologically relevant is indicated
by the fact that BRAP2, which is clearly complexed with HMG20A,
NuMA1 and SYNE2 in the testis, is expressed in some of the same
germ cell types (pachytene spermatocytes) and that in this cell type,
the proteins in question are predominantly cytoplasmic, consistent
with BRAP2's apparent cytoplasmic retention role. The clear implication
is that BRAP2may play a key role in the later stages of spermatogenesis
through modulating subcellular localization of key nuclear/nuclear
envelope proteins.
Of interest is the fact that the three interactors of BRAP2 char-
acterized here for the ﬁrst time, as well as BRAP2 itself, possess
coiled-coil domains, implying that BRAP2-binding partner interaction
may be directly dependent on coiled-coil sequences; speciﬁcity of the
coiled coil interaction between BRAP2 and its binding partners is im-
plied by the data in Supp. Fig. 1. Importantly, although association of
endogenous BRAP2 with NuMA1, SYNE2 and HMG20A is clearly evi-
dent from our co-immunoprecipitation experiments, including in
rodent testis, formal demonstration that binding between BRAP2
and its cargoes is direct remains to be established.results in cytoplasmic localization. A. Plot of affymetrix data (GEO dataset GDS605) for
matogenesis in testes from mice aged 0–56 days as indicated. B. Western analysis for
t: AMT, adult mouse testis lysate; ART, adult rat testis lysate; sg, mouse spermatogonia;
n Bouins-ﬁxed, parafﬁn-embeddedmouse testis sections from Swiss mice. Visualization
ne spermatocytes in 15-day-old, 30-day-old and adult mouse testis sections. Panels in
the relevant sections. Scale bar on 40× objective images is equivalent to 100 μm and
MA1 as per C. HMG20A expression is evident in the nuclei of the early spermatogonia
e testis sections. NuMA1 expression can be seen in the cytoplasm of the pachytene sper-
nd nuclei and cytoplasm of the round spermatids in 30-day-old mouse testis sections.
e relevant sections. Scale bars as per C.
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Fig. 3. BRAP2 can act as a negative regulator of nuclear import of HMG20A and NuMA1. A. Schematic diagram for the domain structure of BRAP2 and the GFP-BRAP2 fusion construct
used. B. COS-7 cells were transfected to express GFP-BRAP2 or GFP alone as indicated (left panels) and ﬁxed and stained for endogenous T-ag (middle panels). C. Digitized images
such as those in B were analyzed to determine the nuclear to cytoplasmic ﬂuorescence ratio of the endogenous T-ag protein in the absence (−) or presence of the indicated
GFP-fusion protein. Results are for the nuclear to cytoplasmic ratio (Fn/c: mean +/− SEM, n = 50). p Values are indicated. D. As for B for CLSM images of COS-7 cells stained
with a HMG20A antibody in the absence or presence of ectopically expressed GFP-BRAP2 or GFP alone. E. Analysis of digitized images such as those in D to determine the nuclear
to cytoplasmic ﬂuorescence ratio of the endogenous HMG20A protein as per C. F. As for B and D for CLSM images of HeLa cells stained with a NuMA1 antibody in the presence of
ectopically expressed GFP-BRAP2. G. Analysis of digitized images such as those in F to determine the nuclear to cytoplasmic ﬂuorescence ratio of the endogenous NuMA1 protein as
per C. ZnF; Zinc ﬁnger, RING; ring ﬁnger.
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Fig. 4. BRAP2 can reduce nuclear envelope localization of SYNE2. COS-7 cells were transfected to express the indicated GFP-fusion proteins (left panels) and ﬁxed and stained for
endogenous SYNE2 (middle right panels). Arrows indicate nuclear rim staining and arrowheads indicate lack of nuclear rim staining as a result of BRAP2 over-expression.
3443R.G. Davies et al. / Biochimica et Biophysica Acta 1833 (2013) 3436–34445. Conclusion
In summary, this study implicates BRAP2 as playing an important
role in the testis in modulating subcellular localization of a range of
testicular proteins, which have roles in the nucleus and/or the nuclear
envelope. Further characterization of its novel binding partners such
as those identiﬁed and validated here, will help establish BRAP2's
potential key role as a regulator of important cellular processes such
as spermatogenesis and other developmental processes [1].
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.05.015.Acknowledgements
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